Deirdre James, MD
Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1033552492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novartis at 29.6% of the total. 2025 is the largest year on record at $691, more than ten times the $23 reported in 2020. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TN, where the typical reported total is $2,871.
Across 66 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$529
- SK Life Science, Inc.$279
- AstraZeneca$251
- Sequel Med Tech, LLC$147
- Madrigal Pharmaceuticals$123
- Neurocrine Biosciences, Inc.$113
- plus $344 from 8 others
Across 33 payments — averaging $2739.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$46K
- AbbVie$44K
What the payments were for
- Food & beverage$1,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $529 |
| SK Life Science, Inc. | 13 | $279 |
| AstraZeneca | 6 | $251 |
| Sequel Med Tech, LLC | 1 | $147 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Neurocrine Biosciences, Inc. | 2 | $113 |
| Neurelis, Inc. | 4 | $81 |
| Novo Nordisk | 1 | $77 |
| Genentech USA, Inc. | 3 | $67 |
| Eisai Inc. | 2 | $34 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Amgen | 2 | $23 |
| GRT US Holding, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,787 in reported general payments places this provider in the 40th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 142 | $199,683 |
| MounjaroTirzepatide | 97 | $118,996 |
| JardianceEmpagliflozin | 75 | $118,423 |
| TrulicityDulaglutide | 46 | $64,757 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $9,270 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $7,740 |
| Novolog FlexpenInsulin Aspart | 32 | $7,303 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $3,870 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $2,822 |
| Sure Comfort Pen NeedlePen Needle, Diabetic | 25 | $2,701 |
| Testosterone | 15 | $1,920 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 17 | $1,212 |
| Levothyroxine Sodium | 88 | $857 |
| Ezetimibe | 23 | $540 |
| Methimazole | 28 | $428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $77 | $199,683142 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $85788 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Memphis
- Alan CohenMemphis$1.4M
- Shimon HararyMemphis$735K
- Samuel Dagogo-JackMemphis$407K
- Aidar GosmanovMemphis$138K
- Malini GuptaMemphis$91K
- Benjamin BrannickMemphis$84K
- Pedro VelasquezMemphis$21K
- Fariha SalmanMemphis$14K
- Maher GhawjiMemphis$13K
- Yunna JiangMemphis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.